Ad is loading...
MENU

ENLV Stock Enlivex Therapeutics (ENLV, $1.3) Aroon Indicator entered a Downtrend on December 03, 2024.

A.I.dvisor
at Tickeron.com
Loading...
ENLV - Enlivex Therapeutics Ltd
Aroon signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Aroon signal
Price: $1.3
Daily change: +$0.22 (+20.37%)
Daily volume: 4.5M
Capitalization: $28.6M
Industry: Biotechnology
For the last three days, A.I.dvisor has detected that ENLV's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong downtrend ahead for ENLV, and traders may view it as a Sell signal for the next month. Traders may consider selling the stock or exploring put options. A.I.dvisor backtested this indicator and found 265 similar cases, of which were successful. Based on this data, the odds of success are

ENLV's Stochastic Oscillator sits in overbought zone for 6 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for ENLV crossed bearishly below the 50-day moving average on November 01, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ENLV broke above its upper Bollinger Band on December 03, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ENLV entered a downward trend on December 03, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ENLV's RSI Indicator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 29, 2024. You may want to consider a long position or call options on ENLV as a result. In of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ENLV just turned positive on November 27, 2024. Looking at past instances where ENLV's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.009) is normal, around the industry mean (14.155). P/E Ratio (0.000) is within average values for comparable stocks, (88.146). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). ENLV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (226.159).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
ENLV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
14 Einstein Street
Phone
+972 26208072
Employees
77
Web
https://www.enlivex.com